JLE

Néphrologie & Thérapeutique

MENU

Standardization of the management of rheumatoid purpura nephropathy in the West of France. What are the repercussions on the renal sequelae? Volume 20, issue 1, February 2024

Figures

Tables

Authors
1 Rennes University Hospital, Department of Pediatrics, Rennes, France
2 Biostatistician in Clinical Pharmacology Department, Rennes University Hospital, Rennes, France
3 Nantes University Hospital, Department of Pediatrics, Nantes, France
4 Brest University Hospital, Department of Pediatrics, Brest, France
5 Tours University Hospital, Department of Pediatrics, Tours, France
* Correspondance : M. Salmon <margaux.salmon@chu-rennes.fr>

Introduction

Rheumatoid purpura is the most common vasculitis in children, and its renal involvement determines the prognosis. To date, no national protocol exists for its management. A protocol was drafted for the French Grand Ouest inter-region in 2011 in order to standardize practices.

Objectives

The main objective is to evaluate renal sequelae with a median follow-up of 2 years since the implementation of this protocol. The secondary objectives are to evaluate the different therapeutic and diagnostic management.

Method

Inclusion of all children from 2006 to 2018 with nephropathy due to rheumatoid purpura followed in the university hospitals of Rennes, Nantes, Tours, Angers and Brest.

Results

169 patients were included, of whom 104 were treated accroding to protocol and 65 differently. Sequels at 2-year follow-up concerned 27.0% of patients with no significant difference according to whether or not the protocol was followed. A significant decrease of 26.1% in the number of renal biopsies was observed in the group that followed the protocol. The latter was performed with a median delay of less than 30 days.

Conclusion

The protocol allowed a standardization of practices without deleterious consequences at 2 years of follow-up and a decrease in renal biopsy punctures. It is in agreement with the recommendations of KDIGO (Kidney Disease Improving Global Outcomes) and European experts. On the other hand, in view of recent studies and the physiopathology, immunosuppressive drugs other than corticosteroids could be introduced earlier in severe forms.